Overview

A Study of LY3556050 in Healthy Participants

Status:
Completed
Trial end date:
2020-08-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Metformin